FDA original new drug approvals in the first quarter of 2025
Abstract
Drug development efforts continue to increase, driven by the ongoing pursuit of innovative, more effective and safer treatments. This article aims to review and analyse new drug applications (NDAs) approved by the United States Food and Drug Administration (FDA) during Q1 of 2025 to provide insight into newly approved drugs and emerging trends in drug development. The evaluation revealed the approval of a total of six new molecular entities (NME) (24%), one new active ingredient (4%), seven new dosage forms (28%), two new combinations (8%), eight new formulations/ new manufacturers (32%), and one medical gas (4%). Approved NMEs are suzetrigine (JournavxTM), a NaV1.8 voltage-gated sodium channel inhibitor that is indicated for pain; gepotidacin (Blujepa™), an antibacterial drug aimed at inhibiting bacterial DNA gyrase and topoisomerase IV for uncomplicated urinary tract infections; fitusiran (Qfitlia™), a double-stranded siRNA designed to specifically inhibit synthesis of antithrombin for hemophilia; an alkylating agent treosulfan (GrafapexTM); a MEK inhibitor mirdametinib (GomekliTM); and CSF1R inhibitor vimseltinib (Romvimza™) targeting cancer/tumors. In conclusion, these works highlight the latest progress and emerging strategies of drug development studies and indicate that drug companies are increasingly shifting their R&D activities to develop innovative treatments with better efficacy & safety profile, transformative medicines with new mod of action to address the…
Read the paper
Related studies
- Noninvasive and Point-of-Care Surface-Enhanced Raman Scattering (SERS)-Based Breathalyzer for Mass Screening of Coronavirus Disease 2019 (COVID-19) under 5 min
- De Novo Transcriptome Analysis and Detection of Antimicrobial Peptides of the American Cockroach Periplaneta americana (Linnaeus)
- Molecular Characterization and Expression Profiling of Tomato GRF Transcription Factor Family Genes in Response to Abiotic Stresses and Phytohormones
- Assembly of Tight Junction Strands: Claudin-10b and Claudin-3 Form Homo Tetrameric Building Blocks that Polymerise in a Channel-Independent Manner
- Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease‐associated variants, common sequence variants, and results from newborn screening
- Machine Learning-Based SERS Chemical Space for Two-Way Prediction of Structures and Spectra of Untrained Molecules
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.